Las Vegas – October 14, 2026 -- SpectroChip Inc. has committed NT$3 million (about US$94,000) over five years to Kaohsiung Municipal Siaogang Hospital under a collaboration with OTC-listed PurMinds Enterprises, Inc. (PFSF) to validate point-of-care (POC) diagnostic technologies.
The funding runs generally at NT$600,000 per year and is subject to the applicable agreement and institutional procedures. It is earmarked for approved teaching and research, which may include research consumables, testing, equipment maintenance, data analysis, research personnel, training and academic exchange. The framework preserves the hospital's independence in professional, clinical, research and procurement decisions.
Three parties plan a joint clinical validation testing center
The parties intend to set up the "PurMinds / SpectroChip Global Clinical Validation Testing Center" to evaluate diagnostic performance, assess testing workflows and pursue improved POC performance. The plan is subject to review by an institutional review board (IRB), institutional approvals and applicable regulatory requirements. The designation does not create a separate legal entity or dedicated physical facility.
Siaogang Hospital is operated by Kaohsiung Medical University. SpectroChip is a Taiwan-based developer of photonic-chip sensing and portable testing technologies.
Each partner takes a defined role
- PurMinds will lead precision-medicine applications, clinical research collaboration and access to international research and industry resources within its global commercialization strategy.
- SpectroChip will supply its photonic chip-based testing technology, technical documentation, training and related support.
- Siaogang Hospital will provide an institutional setting for approved teaching, research and clinical-validation work, including research design, performance evaluation, testing-workflow assessment and talent development.
Specific research projects will be set up through separate written arrangements covering scope, responsibilities, timelines, funding and deliverables. Work involving human participants, specimens, personal data or medical-device clinical studies must follow applicable ethical, regulatory and institutional requirements.
SwiftLab platform targets five-minute quantitative results
PurMinds' SwiftLab Platform places a full-spectrum laboratory-grade spectrometer on a single photonic chip inside the SpectroCision SPU-D100, a portable reader. The platform is designed to convert a low-cost lateral-flow cassette from a yes-or-no line into a quantitative result in five minutes or less. Intended settings include clinics, pharmacies, community health centers and patient bedsides.
PurMinds Founder and CEO Janet Qi said the platform's full-spectrum spectrometry could support an extended catalog of testing items. SpectroChip founder Dr. Cheng-Hao (Kevin) Ko, inventor of the SwiftLab Platform, said the project brings the technology into a structured clinical research environment. Hospital Dean Chih-Hsing Hung said all research will follow applicable ethical, institutional and regulatory requirements.
Regulatory status and risk disclosures limit near-term commercial use
The SpectroCision reader and PurMinds cassettes have not been cleared or approved by the U.S. Food and Drug Administration or licensed by Health Canada, and are not available for clinical use in either country. PurMinds describes itself as a former shell company with limited operating history, no published audited financial statements and a small public float. The company also states that it requires additional capital and depends on third-party licenses and collaborations. The collaboration does not guarantee any research outcome, regulatory authorization, commercialization or financial result.